Targeting treatment using calculated cardiovascular disease risk: effective? A shot in the dark? Or is it time to

T M Reynolds1

  • 1Clinical Chemistry Department, Queen's Hospital, Burton-on-Trent, UK. tim.reynolds@burtonhtr.wmids.nhs.uk

Abstract

Insights

The current cardiovascular screening approach is inefficient. A new diagnostic test could improve patient outcomes by identifying who truly benefits from treatment, saving costs and preventing side effects.

Area of Science:

  • Cardiology
  • Medical Diagnostics
  • Health Economics

Background:

  • Current cardiovascular risk screening uses a 'screen and treat' model.
  • This approach is often ineffective, leading to unnecessary treatments and associated risks for many individuals.

Purpose of the Study:

  • To evaluate a new diagnostic test for cardiovascular disease.
  • To determine if this test can identify patients who will benefit from specific treatments.

Main Methods:

  • The study proposes a shift in screening methodology.
  • Implementation of a diagnostic test prior to treatment initiation.

Main Results:

  • The current 'screen and treat' strategy results in significant numbers of people receiving therapies without benefit.
  • This leads to unnecessary exposure to drug-related risks.

Conclusions:

  • Transitioning to a 'screen, diagnose, and treat' paradigm is recommended.
  • This change has the potential to reduce healthcare costs by avoiding unnecessary drug prescriptions.
  • It can also prevent adverse drug reactions in patients who do not benefit from treatment.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...